Cidara Therapeutics, Inc.
CDTX
$66.96
$2.834.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -418.81% | -153.02% | -242.85% | 19.95% | -76.99% |
| Total Depreciation and Amortization | 67.52% | 19.01% | 49.15% | 44.44% | 129.25% |
| Total Amortization of Deferred Charges | -100.00% | 100.00% | -79.22% | 102.33% | 32.50% |
| Total Other Non-Cash Items | -131.63% | -107.64% | -4.92% | -20.96% | -31.11% |
| Change in Net Operating Assets | -541.36% | -72.35% | 142.27% | -887.40% | -122.37% |
| Cash from Operations | -514.38% | -384.43% | -224.33% | -82.54% | -1,800.45% |
| Capital Expenditure | 67.58% | 75.58% | 74.46% | 8.63% | -49.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 124.16% | 118.20% | 74.46% | 8.63% | -49.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -302.00% | -302.00% | -- | -- | 86.52% |
| Issuance of Common Stock | 6,020,600.00% | 1,230,000.00% | 274.48% | -99.97% | -99.97% |
| Repurchase of Common Stock | -174.36% | 64.33% | 44.06% | 44.06% | 85.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3,525.00% | -- | -- | -- | 99.44% |
| Cash from Financing | 566,552.94% | 28,452.60% | 276.89% | -101.00% | -100.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,746.48% | 153.38% | 722.05% | -1,184.82% | -184.22% |